Guangzhou Innogen Pharmaceutical Group Co Ltd (hkse:02591) Share Price

Company Profile

Business description
Guangzhou Innogen Pharmaceutical Group Co Ltd is a company in Asia to commercialize, a humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It has commercialized Efsubaglutide Alfa (brand name: Diabegone), its Core Product, for the treatment of type 2 diabetes (T2D) in China. Its core business model is to discover, develop and commercialize therapies for diabetes and other metabolic diseases. The company has built a pipeline of drug candidates namely YN014, YN401, YN209, YN202,YN203 targeting diabetes and other metabolic diseases.
Contact
No. 2 Tengfei Second Street
Room 409, Building H Self-numbered Creative Building
China-Singapore Guangzhou Knowledge City
Huangpu District, Guangdong Province
Guangzhou
CHN
https://www.innogenpharm.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
193

Recommended

Profit momentum remains robust yet shares overvalued.

Nathan Zaia | 26 July 2026

The key metrics that matter this earnings season.

Tyger Fitzpatrick | 26 July 2026

Margin recovery remains the key driver for this ASX healthcare share.

Brian Han | 24 July 2026

Index	Last price	Change	% Change
All Ordinaries	9,063.80	36.20	0.40%
CAC 40	8,433.17	60.89	0.73%
DAX 40	25,485.14	386.14	1.54%
Dow JONES (US)	51,947.25	235.60	0.46%
FTSE 100	10,783.54	47.31	0.44%
HKSE	25,207.18	243.95	0.98%
NASDAQ	24,975.82	161.87	-0.64%
Nikkei 225	64,931.19	320.04	0.50%
NZX 50 Index	13,850.69	78.40	0.57%
S&P 500	7,411.98	3.68	0.05%
S&P/ASX 200	8,894.00	36.10	0.41%
SSE Composite Index	3,858.25	44.05	1.15%